Table 1.

Overview of the clinical scenarios for which different questions concerning priority, delay, and omission of therapy had to be answered

Case 1:	Painful osteolytic lesion caused by multiple myeloma in non-weightbearing bones after stabilizing surgery
Case 2:	Osteolytic lesion of multiple myeloma in weightbearing bones (e.g., axial skeleton) without surgery
Case 3:	Limited-stage Hodgkin lymphoma, Ann–Arbor stage II without risk factors after completion of two cycles of ABVD
Case 4, 5:	Diffuse large B‑cell lymphoma with initial abdominal bulky disease after completion of six cycles of R‑CHOP 4) With no information on PET status 5) PET-positive after treatment
Case 6:	Early-stage indolent lymphoma in noncritical location

ABVD adriamycin, bleomycin, vinblastine, dacarbazine; R-CHOP rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone; PET positron emission tomography